ROCKVILLE, Md. & EDMONTON, Alberta / May 05, 2025 / Business Wire / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release first quarter 2025 financial and operational results before markets open on May 12, 2025.
Aurinia’s management team will host a conference call and webcast at 8:30 AM ET that day to review these results and provide a general business update. The link to the audio webcast is available here. To join the conference call, please dial 877-407-9170 / +1 201-493-6756. A replay of the webcast will be available on Aurinia’s website.
About Aurinia
Aurinia Pharmaceuticals is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing AUR200, a dual B cell activating factor (BAFF) and a proliferation inducing ligand (APRIL) inhibitor for the potential treatment of autoimmune diseases.
| Last Trade: | US$11.99 |
| Daily Change: | -0.09 -0.75 |
| Daily Volume: | 692,278 |
| Market Cap: | US$1.580B |
July 31, 2025 June 30, 2025 June 29, 2025 May 12, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
